Omeros (OMER) Current Leases (2018 - 2026)
Omeros recorded quarterly Current Leases of $6.4 million in Q1 2026, up 1.81% quarter-over-quarter from $6.3 million in Q4 2025, and up 5.91% year-over-year from $6.1 million in Q1 2025.
Omeros' Current Leases history runs 9 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Current Leases rose 5.91% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 5.91% YoY), while the FY2025 annual figure was $6.3 million, up 5.51% from the prior year.
- Current Leases came in at $6.4 million for Q1 2026 at Omeros, up from $6.3 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $6.4 million in Q1 2026 to a low of $3.9 million in Q1 2022.
- A 5-year average of $5.3 million and a median of $5.3 million in 2024 frame the typical range for Current Leases.
- Across the five-year window, Current Leases fell 17.98% in 2022 and advanced 20.67% in 2024, its largest moves.
- Omeros' Current Leases stood at $4.3 million in 2022, then climbed by 19.72% to $5.2 million in 2023, then increased by 15.72% to $6.0 million in 2024, then grew by 5.51% to $6.3 million in 2025, then increased by 1.81% to $6.4 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $6.4 million, $6.3 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 6.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.41 Mn |
| Dec 31, 2025 | 6.30 Mn |
| Sep 30, 2025 | 6.18 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 6.06 Mn |
| Dec 31, 2024 | 5.97 Mn |
| Sep 30, 2024 | 5.77 Mn |
| Jun 30, 2024 | 5.57 Mn |
| Mar 31, 2024 | 5.34 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Sep 30, 2023 | 4.89 Mn |
| Jun 30, 2023 | 4.69 Mn |
| Mar 31, 2023 | 4.43 Mn |
| Dec 31, 2022 | 4.31 Mn |
| Sep 30, 2022 | 4.41 Mn |
| Jun 30, 2022 | 4.15 Mn |
| Mar 31, 2022 | 3.93 Mn |
| Dec 31, 2021 | 5.26 Mn |
| Sep 30, 2021 | 5.09 Mn |
| Jun 30, 2021 | 4.87 Mn |
| Mar 31, 2021 | 3.80 Mn |
| Dec 31, 2020 | 3.78 Mn |
| Sep 30, 2020 | 3.75 Mn |
| Jun 30, 2020 | 3.70 Mn |
| Mar 31, 2020 | 3.60 Mn |
| Dec 31, 2019 | 3.50 Mn |
| Sep 30, 2019 | 3.06 Mn |
| Jun 30, 2019 | 2.64 Mn |
| Dec 31, 2018 | 889,000.00 |